We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

New Drug Potentially Effective Against Many Inherited Diseases

By Biotechdaily staff writers
Posted on 18 Feb 2008
A drug that enables correct reading of mutated DNA has been found to partially reverse the symptoms of cystic fibrosis in a mouse model. The drug, PTC124, had already been shown to be effective in treating mice with Duchenne muscular dystrophy, and is being touted as a possible therapeutic agent for the treatment of more than 2,400 inherited diseases caused by nonsense mutations.

Investigators at the University of Alabama (Birmingham, USA) worked with a line of genetically engineered mice that expressed a human CFTR-G542X transgene. The G542X gene carried a nonsense mutation that caused the mice to develop symptoms of cystic fibrosis.

Treatment of the animals with PTC124 suppressed the G542X nonsense mutation and restored a significant amount of human CFTR protein and function. These findings, reported in the February 6, 2008, online edition of the Proceedings of the [U.S.] National Academy of Sciences (PNAS), were confirmed by immunofluorescence staining. Furthermore, functional assays demonstrated that PTC124 treatment restored 24–29% of the average cAMP-stimulated transepithelial chloride currents observed in wild-type mice. These results indicated that PTC124 could effectively suppress the human CFTR-G542X nonsense mutation in vivo.

"Our study shows strong pre-clinical evidence that PTC124 is capable of suppressing nonsense mutations that cause cystic fibrosis,” said senior author Dr. David Bedwell, professor of microbiology at the University of Alabama. "We think this provides strong evidence for clinical trials with PTC124 in CF patients with this kind of mutation.”


Related Links:
University of Alabama

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Platelet Function Analyzer
PL-12
Pipette Calibration System
Artel PCS®
Electrolyte Analyzer
BKE-B

Latest BioResearch News

D-Serine May Predict Immune Checkpoint Therapy Resistance in Gastric Cancer
18 Feb 2008  |   BioResearch

New Genetic Cause Identified for Neurodevelopmental Disorder
18 Feb 2008  |   BioResearch

New Genetic Discovery Could Support Precision Diabetes Care
18 Feb 2008  |   BioResearch